Scotish Equity Partners (SEP), the UK venture capital investor, has made two appointments to its expanding team as the firm looks to broaden its exposure to the UK technology sector.
Andrew Davison has joined SEP as investment director, becoming part of the company’s investment management group. He joins from 3i where he spent six years in the firm’s technology division. Whilst at 3i he worked on numerous transactions including investments in Roslin Biomed, Kamelian, Quadstone, Aspects Software, Intense Photonics and the MBO of Kingston SCL.
Also joining the firm is Julie Curran, currently an analyst at the London office of the biosciences consultancy, Decision Resources. Curran will join the firm’s biotechnology team, which is led by SEP investment director Brian Kerr.
SEP says it plans to make at least two further senior appointments over the coming months as it looks to grow its London offices, opened in March this year. The firm wants to take advantage of what it sees as a growing deal flow in the south east. The firm is also looking to expand into the rest of the UK.
Scottish Equity Partners says it invests in technology businesses and other high growth companies across the UK and Ireland. SEP is currently investing from its £110m venture capital fund launched in January 2001.